The Medicines (MDCO) Receives News Sentiment Rating of 0.17
Media stories about The Medicines (NASDAQ:MDCO) have been trending somewhat positive on Saturday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. The Medicines earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.7887719549355 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- The Medicines Company (NASDAQ:MDCO) – Top RSI Trades for … – The Investor Guide (wallstreetnews24.com)
- Chardan Capital Reaffirms “Buy” Rating for The Medicines Company (MDCO) (americanbankingnews.com)
- The Medicines Company (NASDAQ:MDCO) – Hot Stock to Track – The Investor Guide (wallstreetnews24.com)
- Zacks: Analysts Anticipate The Medicines Company (MDCO) to Announce -$1.58 EPS (americanbankingnews.com)
MDCO has been the topic of a number of recent analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $85.00 price target (up previously from $80.00) on shares of The Medicines in a research note on Tuesday, August 29th. ValuEngine raised shares of The Medicines from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised shares of The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research note on Tuesday, August 8th. Jefferies Group LLC reaffirmed a “buy” rating and set a $54.00 price target on shares of The Medicines in a research note on Thursday, September 14th. Finally, Citigroup Inc. increased their price target on shares of The Medicines from $43.00 to $45.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. The Medicines presently has an average rating of “Buy” and an average price target of $54.00.
The Medicines (NASDAQ MDCO) opened at 35.44 on Friday. The stock’s market cap is $2.55 billion. The stock has a 50 day moving average of $36.16 and a 200-day moving average of $42.45. The Medicines has a 52 week low of $30.80 and a 52 week high of $55.95.
The Medicines (NASDAQ:MDCO) last posted its earnings results on Wednesday, August 9th. The company reported ($5.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.29) by ($4.23). The business had revenue of $18.74 million during the quarter, compared to the consensus estimate of $29.64 million. The Medicines had a negative return on equity of 137.20% and a negative net margin of 670.46%. The business’s revenue was down 65.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) earnings per share. Analysts forecast that The Medicines will post ($9.69) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/23/the-medicines-mdco-receives-news-sentiment-rating-of-0-17.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.